Shire

BMS appoints Judge as senior vice president, human resources

Thursday, February 21, 2013 08:00 AM

Global biopharmaceutical company Bristol-Myers Squibb (BMS) has appointed Ann Powell Judge as senior vice president, Human Resources.

More... »


Shire to acquire Lotus Tissue Repair

Wednesday, January 9, 2013 09:45 AM

Shire, a global specialty biopharmaceutical company, has signed an agreement to acquire Lotus Tissue Repair, a Cambridge, Mass.-based biotechnology company developing the first and only protein replacement therapy currently being investigated for the treatment of dystrophic epidermolysis bullosa (DEB).

More... »


Ambrx appoints Macartney as CEO

Tuesday, January 8, 2013 08:00 AM

Ambrx, a clinical-stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, has appointed Lawson Macartney, Ph.D., DVM, as president and CEO of the company and a member of the board of directors.

More... »

ethris, Shire form research-based alliance on SNIM modified RNA

Monday, January 7, 2013 09:57 AM

Shire, a global specialty biopharmaceutical company, and ethris, a young biopharmaceutical company based in Germany, have initiated a research based alliance focused on the development and commercialization of novel RNA-based therapeutics.

More... »

Arrowhead, Shire ink agreement to develop peptide-targeted therapeutics

Wednesday, December 19, 2012 09:41 AM

Arrowhead Research, a clinical stage targeted therapeutics company, has signed a research collaboration and license agreement with Shire, a specialty biopharmaceutical company, to develop and commercialize targeted peptide-drug conjugates (PDCs) by utilizing Arrowhead's human-derived Homing Peptide platform and Shire's therapeutic payloads.

More... »

Jeff Jonas joins Shire leadership team

Tuesday, November 20, 2012 11:51 AM

Irish specialty biopharmaceutical company Shire has appointed Jeff Jonas, MD, as president of Shire's regenerative medicine business.

More... »

Shire, Boston Children's Hospital collaborate on rare pediatric diseases

Tuesday, November 20, 2012 10:54 AM

Boston Children’s Hospital and Shire, a specialty biopharmaceutical company based in Ireland, have signed a three-year, broad research collaboration in rare diseases.

More... »

Shire’s Angus Russell to retire in 2013, Ornskov to succeed as CEO

Friday, October 26, 2012 12:07 PM

The board of directors of Shire, a global specialty biopharmaceutical company based in Ireland, has announced the retirement in 2013 of chief executive Angus Russell after 13 years with the company and 32 years in the pharmaceutical industry.

More... »

AMRI, Shire ink 5-year extension of API supply agreement

Monday, October 22, 2012 12:22 PM

AMRI, a global contract research and manufacturing organization, has entered into a multi-year supply agreement for an undisclosed product with Shire U.S. Manufacturing, a subsidiary of specialty biopharmaceutical company Shire.

More... »

Y-Prime names Greef as senior business analyst

Thursday, August 30, 2012 02:53 PM

Y-Prime Technologies, an Malvern, Penn.-based eClinical products and life sciences consulting services company, has expanded its international operations in Europe and has named Jeanette Anne Greef as senior business analyst in the U.K. office.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs